CR6861A - IMIDAZOL DERIVATIVES - Google Patents
IMIDAZOL DERIVATIVESInfo
- Publication number
- CR6861A CR6861A CR6861A CR6861A CR6861A CR 6861 A CR6861 A CR 6861A CR 6861 A CR6861 A CR 6861A CR 6861 A CR6861 A CR 6861A CR 6861 A CR6861 A CR 6861A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- formula
- syndrome
- treat
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
LA INVENCION PROPORCIONA COMPUESTOS DE FORMULA EN LA QUE R1,R2,R3 Y R4, SON COMO SE HAN DEFINIDO Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. SE INDICA QUE LOS COMPUESTOS DE FORMULA I TIENEN ACTIVIDAD INHIBIDORA CDK5, CDK 2 Y GSK3. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS QUE COMPRENDEN COMPUESTOS DE FORMULA I PARA TRATAR Y PREVENIR ENFERMEDADES Y AFECCIONES QUE COMPRENDEN UN CRECIMIENTO CELULAR ANORMAL, TAL COMO EL CANCER, ENFEMEDADES Y AFECCIONES NEURODEGENERATIVAS Y LAS AFECTADAS POR LA NEUROTRANSMISION DE DOPAMINA. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS QUE COMPRENDEN COMPUESTOS DE FORMULA I PARA TRATAR AL FERTILIDAD MASCULINA Y MOTILIDAD DE LOS ESPERMATOZOIDES, DIABETES MELLITUS, DISMINUCION DE LA TOLERANCIA A LA GLUCOSA, SINDROME METABOLICO O SINDROME X, SINDROME DE OVARIOS POLIQUISTICOS, ADIPOGENESIS Y OBESISDAD, MIOGENESIS Y DEBILIDAD, POR EJEMPLO, LA REDUCCION DEL RENDIMIENTO FISICO RELACIONADA CON LA EDAD, SARCOPENIA AGUDA, POR EJEMPLO, ATROFIA MUSCULAR Y/O CAQUEXIA ASOCIADA A QUEMADURAS, REPOSO EN CAMA, INMOVILIZACION DE MIEMBROS O CIRUGIA TORACICA, ABDOMINAL Y/U ORTOPEDICA DEL CABELLO Y CALVICIE E INMUNODEFICIENCIA.THE INVENTION PROVIDES FORMULA COMPOUNDS IN WHICH R1, R2, R3 AND R4 ARE AS DEFINED AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS. IT IS INDICATED THAT THE FORMULA I COMPOUNDS HAVE INHIBITING ACTIVITY CDK5, CDK 2 AND GSK3. PHARMACEUTICAL COMPOSITIONS AND PROCEDURES THAT INCLUDE FORMULA COMPOUNDS ARE ALSO DESCRIBED TO TREAT AND PREVENT DISEASES AND AFFECTIONS THAT INCLUDE ABNORMAL CELLULAR GROWTH, SUCH AS CANCER, DISEASES AND AFFECTURED OPENING THEMES. ALSO DESCRIBED pharmaceutical compositions and methods comprising compounds of formula I TO TREAT THE MALE FERTILITY AND sperm motility, diabetes mellitus, reduced tolerance to glucose, METABOLIC SYNDROME or syndrome X, polycystic ovary syndrome, adipogenesis and OBESISDAD, MIOGENESIS AND WEAKNESS, FOR EXAMPLE, THE REDUCTION OF PHYSICAL PERFORMANCE RELATED TO AGE, ACUTE SARCOPENIA, FOR EXAMPLE, MUSCLE ATROPHY AND / OR CAQUEXY ASSOCIATED WITH BURNS, REST IN BED, IMMOBILIZATION OR DIVISION OF ORMOBILIZATION HAIR AND CALVICIE AND IMMUNODEFICIENCY.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22172400P | 2000-07-31 | 2000-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR6861A true CR6861A (en) | 2004-03-11 |
Family
ID=22829075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR6861A CR6861A (en) | 2000-07-31 | 2002-12-18 | IMIDAZOL DERIVATIVES |
Country Status (35)
Country | Link |
---|---|
EP (1) | EP1305295A1 (en) |
JP (2) | JP4166084B2 (en) |
KR (1) | KR20030019644A (en) |
CN (1) | CN1444567A (en) |
AP (1) | AP2001002232A0 (en) |
AR (1) | AR032629A1 (en) |
AU (1) | AU2001270944A1 (en) |
BG (1) | BG107469A (en) |
BR (1) | BR0112862A (en) |
CA (1) | CA2418115A1 (en) |
CR (1) | CR6861A (en) |
CZ (1) | CZ2003225A3 (en) |
DO (1) | DOP2001000220A (en) |
EA (1) | EA200300097A1 (en) |
EC (1) | ECSP034445A (en) |
EE (1) | EE200300049A (en) |
GT (1) | GT200100147A (en) |
HR (1) | HRP20030048A2 (en) |
HU (1) | HUP0303069A3 (en) |
IL (1) | IL153787A0 (en) |
IS (1) | IS6662A (en) |
MA (1) | MA26932A1 (en) |
MX (1) | MXPA03000939A (en) |
NO (1) | NO20030472L (en) |
NZ (1) | NZ523272A (en) |
OA (1) | OA12345A (en) |
PA (1) | PA8523701A1 (en) |
PE (1) | PE20020337A1 (en) |
PL (1) | PL365134A1 (en) |
SK (1) | SK1042003A3 (en) |
SV (1) | SV2002000571A (en) |
TN (1) | TNSN01114A1 (en) |
UY (1) | UY26862A1 (en) |
WO (1) | WO2002010141A1 (en) |
ZA (1) | ZA200300819B (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
SI1478358T1 (en) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
CA2487948A1 (en) | 2002-06-14 | 2003-12-24 | Applied Research Systems Ars Holding N.V. | Azole methylidene cyanide derivatives and their use as protein kinase modulators |
US7141561B2 (en) | 2002-07-25 | 2006-11-28 | Sanofi-Aventis Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
DE10233817A1 (en) * | 2002-07-25 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Substituted diaryl heterocycles, process for their preparation and their use as medicaments |
GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
DK1636585T3 (en) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurines with kinase inhibitory activity |
CL2004001834A1 (en) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | COMPOUND 4- {4- [3- (4-CHLORO-3-TRIFLUOROMETILFENIL) -UREIDO] -3-FLUOROFENOXI} -PIRIDIN-2-METHYLAMIDE, RAF INHIBITOR, VEGFR, P38 AND PDGFR KINASES, ITS SALTS; PHARMACEUTICAL COMPOSIICON; PHARMACEUTICAL COMBINATION; AND ITS USE TO TREAT HYPERPROL DISORDERS |
GEP20084420B (en) | 2004-03-23 | 2008-07-10 | Pfizer Prod Inc | Use of imidazole compounds for the treatment of neurodegenerative disorders |
CN101010315A (en) | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
US7928264B2 (en) | 2004-09-21 | 2011-04-19 | Astellas Pharma Inc. | Aminoalcohol derivatives |
WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
KR20080040010A (en) * | 2005-09-22 | 2008-05-07 | 화이자 프로덕츠 인코포레이티드 | Imidazole compounds for the treatment of neurological disorders |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US7514566B2 (en) | 2006-01-18 | 2009-04-07 | Amgen, Inc. | Thiazole compounds and methods of use |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
JP5406030B2 (en) | 2006-10-21 | 2014-02-05 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
WO2009017453A1 (en) * | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
JP5756011B2 (en) * | 2008-04-24 | 2015-07-29 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | 1- (7- (Hexahydropyrrolo [3,4-C] pyrrol-2 (1H) -yl) quinolin-4-yl) -3- (pyrazine-2) as glycogen synthase kinase 3 (GSK-3) -Yl) urea derivatives and related compounds |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2621914B1 (en) | 2010-09-27 | 2016-12-28 | Abbott GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
AU2013355054B2 (en) | 2012-12-07 | 2017-08-24 | Chemocentryx, Inc. | Diazole lactams |
PT2935227T (en) * | 2012-12-21 | 2017-12-06 | Chemocentryx Inc | Diazole amides as ccr1 receptor antagonists |
US10653672B2 (en) | 2014-02-07 | 2020-05-19 | National University Corporation Tokyo Medical And Dental University | Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator |
ES2775734T3 (en) * | 2015-08-31 | 2020-07-28 | Nutramax Lab Inc | Compositions comprising magnolia, felodendron, theanine and / or whey protein |
GB201605126D0 (en) | 2016-03-24 | 2016-05-11 | Univ Nottingham | Inhibitors and their uses |
JP2019510832A (en) | 2016-04-07 | 2019-04-18 | ケモセントリクス,インコーポレーテッド | Reduction of tumor burden by administering a CCR1 antagonist in combination with a PD-1 inhibitor or PD-L1 inhibitor |
CN107698567B (en) * | 2017-10-25 | 2020-09-15 | 西南大学 | Isatin azole alcohol compound and preparation method and medical application thereof |
US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
GB201908424D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Novel compounds |
US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
US10590087B1 (en) | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
CN112250636A (en) * | 2020-11-09 | 2021-01-22 | 广西科技大学 | 5-aminoimidazole compound and synthesis method thereof |
US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
ZA987385B (en) * | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
ZA987383B (en) * | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
ATE274510T1 (en) * | 1998-06-19 | 2004-09-15 | Chiron Corp | GLYCOGEN SYNTHASE KINASE 3 INHIBITORS |
WO2000021550A2 (en) * | 1998-10-13 | 2000-04-20 | President And Fellows Of Harvard College | Methods and compositions for treating neurodegenerative diseases |
CO5160260A1 (en) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | SECRETAGOGOS OF THE HORMONE OF GROWTH DERIVED FROM IMI- DAZOL 1,4- SUBSTITUTED |
ES2213996T3 (en) * | 1999-12-08 | 2004-09-01 | Centre National De La Recherche Scientifique (Cnrs) | USE OF HYMENIALDISINE OR ITS DERIVATIVES IN THE MANUFACTURE OF MEDICINES. |
-
2001
- 2001-07-23 GT GT200100147A patent/GT200100147A/en unknown
- 2001-07-25 HU HU0303069A patent/HUP0303069A3/en unknown
- 2001-07-25 PE PE2001000752A patent/PE20020337A1/en not_active Application Discontinuation
- 2001-07-25 MX MXPA03000939A patent/MXPA03000939A/en active IP Right Grant
- 2001-07-25 CN CN01813397A patent/CN1444567A/en active Pending
- 2001-07-25 NZ NZ523272A patent/NZ523272A/en unknown
- 2001-07-25 CA CA002418115A patent/CA2418115A1/en not_active Abandoned
- 2001-07-25 EE EEP200300049A patent/EE200300049A/en unknown
- 2001-07-25 EA EA200300097A patent/EA200300097A1/en unknown
- 2001-07-25 JP JP2002516273A patent/JP4166084B2/en not_active Expired - Fee Related
- 2001-07-25 KR KR10-2003-7001455A patent/KR20030019644A/en not_active Application Discontinuation
- 2001-07-25 CZ CZ2003225A patent/CZ2003225A3/en unknown
- 2001-07-25 WO PCT/IB2001/001335 patent/WO2002010141A1/en not_active Application Discontinuation
- 2001-07-25 OA OA1200300017A patent/OA12345A/en unknown
- 2001-07-25 PL PL01365134A patent/PL365134A1/en not_active Application Discontinuation
- 2001-07-25 BR BR0112862-0A patent/BR0112862A/en not_active IP Right Cessation
- 2001-07-25 SK SK104-2003A patent/SK1042003A3/en not_active Application Discontinuation
- 2001-07-25 AU AU2001270944A patent/AU2001270944A1/en not_active Abandoned
- 2001-07-25 EP EP01949833A patent/EP1305295A1/en not_active Withdrawn
- 2001-07-25 IL IL15378701A patent/IL153787A0/en unknown
- 2001-07-26 AP APAP/P/2001/002232A patent/AP2001002232A0/en unknown
- 2001-07-27 SV SV2001000571A patent/SV2002000571A/en not_active Application Discontinuation
- 2001-07-27 DO DO2001000220A patent/DOP2001000220A/en unknown
- 2001-07-30 TN TNTNSN01114A patent/TNSN01114A1/en unknown
- 2001-07-30 UY UY26862A patent/UY26862A1/en not_active Application Discontinuation
- 2001-07-30 AR ARP010103637A patent/AR032629A1/en unknown
- 2001-07-31 PA PA20018523701A patent/PA8523701A1/en unknown
-
2002
- 2002-12-18 CR CR6861A patent/CR6861A/en not_active Application Discontinuation
- 2002-12-19 IS IS6662A patent/IS6662A/en unknown
-
2003
- 2003-01-16 BG BG107469A patent/BG107469A/en unknown
- 2003-01-20 MA MA27004A patent/MA26932A1/en unknown
- 2003-01-22 EC EC2003004445A patent/ECSP034445A/en unknown
- 2003-01-24 HR HR20030048A patent/HRP20030048A2/en not_active Application Discontinuation
- 2003-01-29 ZA ZA200300819A patent/ZA200300819B/en unknown
- 2003-01-30 NO NO20030472A patent/NO20030472L/en not_active Application Discontinuation
-
2008
- 2008-05-19 JP JP2008131176A patent/JP2008255123A/en not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR6861A (en) | IMIDAZOL DERIVATIVES | |
SV2002000618A (en) | DERIVATIVES OF PIRAZOL REF. PC10769 / 700007 / BB | |
BR0201691A (en) | Thiazole Derivatives | |
PA8593101A1 (en) | COMPOSITIONS FOR THE TREATMENT OF ABNORMAL CELL GROWTH | |
CR8147A (en) | PIRIDO DERIVATIVES 2, 1A-ISOQUINOLINE, AS DPP-IV INHIBITORS | |
EP1609798A4 (en) | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | |
HUP0401642A2 (en) | Use of staurosporine derivatives for the preparation of pharmaceutical compositions | |
PA8487601A1 (en) | USEFUL SUBSTITUTED BICYCLE DERIVATIVES AS AGENTS AGAINST CANCER | |
CO4810375A1 (en) | DERIVATIVES OF 9-AMINO-3-KETO Erythromycin | |
NO20064412L (en) | Condensed heterocycle derivative, medical composition containing the same and medical use thereof | |
BRPI0416212A (en) | pyridazinone derivative, pharmaceutical composition, use of the derivative, method for treating a subject afflicted with a condition or disease amenable to phosphodiesterase 4 inhibition and combination product | |
TW200621762A (en) | Novel compounds | |
AR020032A1 (en) | DERIVATIVES OF 1,3-METHYL Erythromycin. | |
BRPI0518785A2 (en) | 7-membered ring compound and method of production and pharmaceutical application thereof | |
HUP0201284A2 (en) | Preventive or therapeutic drugs for fibrosis containing quinazolindione derivative chymase inhibitors as the active ingredient | |
HUP0002963A2 (en) | Use of pyrazolo-[4,3-d] pyrimidinon derivatives for the production of pharmaceutical compositions for treating diseases of the eye field | |
DOP2002000519A (en) | PROCEDURE FOR THE PREPARATION OF SUBSTITUTED BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH | |
MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
PA8450901A1 (en) | Erythromycin derivatives | |
PE20030236A1 (en) | DERIVATIVES OF BENZIMIDAZOLE 1-ARIL-2-N, S- OR O-SUBSTITUTES, OBTAINING DRUGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES | |
WO2007075092A8 (en) | New derivatives of epirubicin, their medicinal application and pharmaceuticals acceptable forms of drugs | |
PA8474401A1 (en) | 3-KETO TRICYCLIC DERIVATIVES OF 6-0-METHYLERITHROMYCIN | |
AR049343A1 (en) | THIOETER DERIVATIVES, THEIR OBTAINING AND USE OF THE SAME AS PHARMACEUTICAL AGENTS | |
ATE425741T1 (en) | MEDICINAL PREPARATION AND ITS USE FOR THE TREATMENT OF DISEASES OF THE INNER EAR | |
ECSP982501A (en) | Erythromycin derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |